CD19 and B-cell non-Hodgkin lymphoma: In mouse models of BCR-ABL1+ B-ALL and B-cell lymphoma, CD19@NP/17-DMAG, both alone and in combination with TKIs like imatinib and ponatinib, demonstrated significant efficacy by reducing tumor burden, prolonging survival, and activating a strong anti-tumor T-cell response.